Immunovia has announced the appointment of Karl Stone as Chief Operating Officer effective 1 March, 2023.
Immunovia has added a new Chief Operating Officer role to its executive team to align with strategic priorities and focus on the US commercialization of the IMMray PanCan-d test, it states. The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.
“We are very excited to welcome Karl to Immunovia’s executive management team. His experience will play an important role in executing on our strategic priorities in this critical phase of the company’s development as we further progress the commercialization of the IMMray PanCan-d test. Karl’s background in leading operations will further ensure streamlined performance across all departments,” says Philipp Mathieu, CEO and President of Immunovia.
Karl Stone
Karl Stone brings over 25 years of technical work experience from industrial bioprocessing through genomics, to IVD; he also has extensive experience in developing and commercializing IVD systems. He was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology, describes Immunovia. During the pandemic he was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab – one of the UK’s network of COVID testing labs. He has also held leadership roles in operations, engineering and consulting across the life sciences industry. He holds a Ph.D. in Biochemical Engineering from University College London, an M.Sc. in Medical Electronics and Physics from the University of London, and a B.Sc. in Electrical and Electronic Engineering from King’s College London.
Photo: Immunovia
